Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2013
03/14/2013WO2013034087A1 Doripenem hydrate crystal and preparation method therefor
03/14/2013WO2013034048A1 Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
03/14/2013WO2013034047A1 Heterocyclic-substitued benzofuran derivatives and methods of use thereof for the treatment of viral diseases
03/14/2013WO2013034040A1 Celecoxib solid dispersion and preparation method therefor
03/14/2013WO2013033981A1 2,7-naphthyridine derivative, preparation method therefor and use thereof
03/14/2013WO2013033971A1 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
03/14/2013WO2013033901A1 Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
03/14/2013WO2013033900A1 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
03/14/2013WO2013033899A1 Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
03/14/2013WO2013033862A1 4-substituted-(3-substituted-1h-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof
03/14/2013WO2013033802A1 Antimicrobial compositions and uses thereof
03/14/2013WO2013033797A1 Pharmaceutical composition for treatment of burns and injuries of the skin and its preparation process
03/14/2013WO2013018104A3 Extraction of vitamin e from plant matter
03/14/2013WO2013013113A3 Histone deacetylase 6 selective inhibitors for the treatment of bone disease
03/14/2013WO2013012665A3 Permanent attachment of pigments and dyes to surfaces containing calkyl-oh functionality
03/14/2013WO2013005170A3 Inhibitors of aquaglyceroporins, methods and uses thereof
03/14/2013WO2013003731A3 Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
03/14/2013WO2012178122A3 Phenocopy model of disease
03/14/2013WO2012176061A9 Trpv1 antagonists including dihydroxy substituent and uses thereof
03/14/2013WO2012174126A8 METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY
03/14/2013WO2012173682A3 Compounds and methods for the treatment of isocitrate dehydrognase related diseases
03/14/2013WO2012173581A4 Thiocolchicoside, etodolac and famotidine combinations
03/14/2013WO2012173392A3 Curcuminoid-based compound/stevioside-containing complex for the prevention and treatment of an influenza virus infection
03/14/2013WO2012173383A3 Skin composition for external use containing cryptotanshinone as active ingredient
03/14/2013WO2012173382A3 Skin composition for external use containing tanshinone ii a as active ingredient
03/14/2013WO2012169863A3 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
03/14/2013WO2012166778A3 Conjugates of nitroimidazoles and their use as chemotherapeutic agents
03/14/2013WO2012162211A3 Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor gw4869 for degenerative neurological disorders
03/14/2013WO2012158197A3 Compounds useful as akt/pkb modulators and uses thereof
03/14/2013WO2012157980A9 Manufacturing method of azilsartan
03/14/2013WO2012157977A9 Manufacturing method of heterocyclic compound
03/14/2013WO2012149393A3 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
03/14/2013WO2012149282A3 Tolerogenic synthetic nanocarriers for generating cd8+regulatory t cells
03/14/2013WO2012149252A3 Tolerogenic synthetic nanocarriers
03/14/2013WO2012145653A3 Therapeutic combinations for use in neoplasia
03/14/2013WO2012142029A3 Serms for the treatment of estrogen receptor-mediated disorders
03/14/2013WO2012138846A3 Method and compositions comprising small rna agonist and antagonists to modulate inflammation
03/14/2013WO2012138691A3 Diagnosis and treatment of taxane-resistant cancers
03/14/2013WO2012135805A3 Delivery and formulation of engineered nucleic acids
03/14/2013WO2012135528A3 Galectin-3c combination therapy for human cancer
03/14/2013WO2012129073A3 Compositions and methods for tissue engineering and cell based therapies
03/14/2013WO2012127277A3 Bendamustine anionic-catioinic cyclopolysaccharide compositions
03/14/2013WO2012120541A3 Amorphous form of lopinavir and ritonavir mixture
03/14/2013WO2012112862A3 Treating mycobacterial infection with cu+/++ boosting therapeutics
03/14/2013WO2012112841A3 [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
03/14/2013WO2012110440A9 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors
03/14/2013WO2012104655A3 Compostions and methods for treating chronic inflammation and inflammatory diseases
03/14/2013WO2012079059A3 Post-treatment breast cancer prognosis
03/14/2013WO2012068463A3 Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
03/14/2013WO2011128388A3 Oxazole and thiazole compounds as ksp inhibitors
03/14/2013WO2011069474A3 Oxidized derivative of hyaluronic acid, a method of preparation thereof and a method of modification thereof
03/14/2013WO2010062171A3 Cc-1065 analogs and their conjugates
03/14/2013US20130067609 Mammalian Genes Involved in Tularemia and Other Infections
03/14/2013US20130067607 Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
03/14/2013US20130067606 Modulating production traits in avians
03/14/2013US20130066264 Sugar-responsive gel and medicine administering device
03/14/2013US20130066256 Treatment of Acne Using Derivatives of 5-Aminolevulinic Acid
03/14/2013US20130066069 Processes for preparing substituted pyrimidines
03/14/2013US20130066058 Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1
03/14/2013US20130065967 Use of methylsulfonylmethane (msm) to inhibit microbial activity
03/14/2013US20130065966 Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses
03/14/2013US20130065965 Di(4-chloro-phenyldiguanido) derivative which is free of potential genotoxicity and a process for reducing the residual amount of p-chloroaniline in said di(4-chloro-phenyldiguanido) derivative
03/14/2013US20130065964 Peritoneal dialysis solution
03/14/2013US20130065963 Histone Deacetylase Inhibitors and Methods of Use Thereof
03/14/2013US20130065962 Compounds For Use In The Treatment Of Diseases
03/14/2013US20130065961 Modulation of physiological processes and agents useful for same
03/14/2013US20130065960 Method for producing powder mixture
03/14/2013US20130065957 Diclofenac salt of tramadol
03/14/2013US20130065956 Composition and/or method for preventing onset and/or recurrence of cardiovascular events
03/14/2013US20130065955 Crystalline forms of cabazitaxel
03/14/2013US20130065954 Ophthalmic uses of s1p receptor modulators
03/14/2013US20130065953 Phenotypic reversion of pancreatic carcinoma cells
03/14/2013US20130065952 Tumor-specific promoter and oncolytic virus vector comprising the same
03/14/2013US20130065951 Compositions and methods related to mirna modulation of neovascularization or angiogenesis
03/14/2013US20130065950 Modified oligonucleotides for telomerase inhibition
03/14/2013US20130065949 Microrna mirna-31 as a therapeutic approach for the treatment of cancer
03/14/2013US20130065948 Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
03/14/2013US20130065947 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
03/14/2013US20130065946 Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155
03/14/2013US20130065945 Nlk as a marker for diagnosis of liver cancer and as a therapeutic agent thereof
03/14/2013US20130065944 Reverse micelle system comprising nucleic acids and use thereof
03/14/2013US20130065943 Compositions and methods for inhibiting expression of cd45 gene
03/14/2013US20130065942 Nucleic Acid-Lipopolymer Compositions
03/14/2013US20130065941 Compositions and their uses for gene therapy of bone conditions
03/14/2013US20130065940 Double-stranded rna molecules with stability in mammalian body fluid, preparation and application thereof
03/14/2013US20130065939 Compositions and methods for silencing genes expressed in cancer
03/14/2013US20130065938 Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer
03/14/2013US20130065937 Novel prenylarene compound and use thereof
03/14/2013US20130065936 Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
03/14/2013US20130065935 Novel Inhibitors of the Amino Acid Transporters ASCT1 and ASCT2
03/14/2013US20130065934 Fatty acid cox inhibitor derivatives and their uses
03/14/2013US20130065933 Pharmaceutical composition for peroral administration of diindolylmethane
03/14/2013US20130065932 Process for the isolation of organic compounds useful for the treatment of cancer
03/14/2013US20130065930 Topical composition
03/14/2013US20130065929 Use of Pyridoxamine to Treat and/or Prevent Disease Processes
03/14/2013US20130065928 Biomarkers for pi3k-driven cancer
03/14/2013US20130065927 Forms of dexlansoprazole and processes for the preparation thereof
03/14/2013US20130065926 N-piperidinyl acetamide derivatives as calcium channel blockers
03/14/2013US20130065925 Pyrrolidin-3-ylacetic acid derivative
03/14/2013US20130065924 Composition and method for the treatment of neurodegeneration
1 ... 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 ... 7860